

Liver and kidney function in patients with Covid-19 treated with remdesivir

Sylvia van Laar¹, M De Boer¹, Kim Gombert-Handoko¹, HJ Guchelaar¹, and Juliette Zwaveling¹

¹Leiden University Medical Center

January 14, 2021

Abstract

For the treatment of Covid-19 patients with remdesivir, poor renal- and liver function were both exclusion criteria in randomized clinical trials (RCTs) and contra-indication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal- and liver functions of covid-19 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met RCT exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate larger than 10 ml/min/1.73m². Also, 25% and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, contra-indications based on kidney- and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly.

Hosted file

short report 71JZ.pdf available at <https://authorea.com/users/389421/articles/504029-liver-and-kidney-function-in-patients-with-covid-19-treated-with-remdesivir>

